Loading...
Loading...
BFRI| Name | Value |
|---|---|
| Revenues | 9,012.0K |
| Cost of Revenue | 4,877.0K |
| Gross Profit | 4,135.0K |
| Operating Expense | 9,095.0K |
| Operating I/L | -4,960.0K |
| Other Income/Expense | -706.0K |
| Interest Income | 17.0K |
| Pretax | -5,666.0K |
| Income Tax Expense | 3.0K |
| Net Income/Loss | -5,669.0K |
Biofrontera Inc. is a biopharmaceutical company specializing in the commercialization of pharmaceutical products for dermatological conditions in the United States. Its flagship product, Ameluz, is a prescription drug used in combination with the RhodoLED lamp series for photodynamic therapy to treat actinic keratosis. Additionally, the company offers Xepi, a prescription cream for impetigo treatment. Biofrontera generates revenue through the sale of these prescription drugs and medical devices, catering to the needs of patients with dermatological conditions.
